Inhibition of cleavage of TLR2 by ADAM17 may or may not be helpful for either cancer or inflammatory processes as soluble TLR2 ectodomain can negatively regulate TLR2 activation by behaving as a decoy receptor [114]. The gene discussed is TLR2; the disease is cancer.